The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VAXX | -95% | N/A | N/A | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +45% |
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s, Parkinson’s, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL.
Investors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one.
Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.
| Q4 2023 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.46M | 0.0% |
| Market Cap | $107.73M | 0.0% |
| Market Cap / Employee | $1.89M | 0.0% |
| Employees | 57 | 0.0% |
| Net Income | -$11.39M | 0.0% |
| EBITDA | -$11.19M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2023 | YOY Change | |
|---|---|---|
| Net Cash | $5.04M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Long Term Debt | $13.26M | 0.0% |
| Short Term Debt | $1.91M | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Return On Assets | -75.49% | 0.0% |
| Return On Invested Capital | 38.03% | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12.26M | 0.0% |
| Operating Free Cash Flow | -$11.85M | 0.0% |
| Metric | Q4 2023 | YoY Change |
|---|---|---|
| Price to Book | 4.54 | - |
| Price to Tangible Book Value | 4.54 | - |
| Enterprise Value to EBITDA | -8.25 | - |
| Return on Equity | -150.6% | - |
| Total Debt | $15.17M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
